BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
917 results:

  • 1. Prediction of Responsiveness to pd-l1/PD-1 Inhibitors Using miRNA Profiles Associated With pd-l1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
    Koh YW; Han JH; Haam S; Lee HW
    Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. SLC7A11 inhibits ferroptosis and downregulates pd-l1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Case report: Pathological complete response induced by immunochemotherapy in a case of Pulmonary Sarcomatoid Carcinoma staged IIIA-N2.
    Guo Y; Liu X; Tang H; Qiu Z; Ma F; Hu A; Liu C; Wang Y
    Front Immunol; 2024; 15():1374270. PubMed ID: 38650938
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
    Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
    BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
    Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
    Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
    Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
    Xu K; Lu W; Yu A; Wu H; He J
    BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The Expression and Prognostic Significance of ICOS in NSCLC Integrated Pan-cancer and Multi-Omics Analyses.
    Chen M; Yan X; Hong B; Xiao Y; Qian Y
    Int J Med Sci; 2024; 21(5):795-808. PubMed ID: 38616999
    [No Abstract]    [Full Text] [Related]  

  • 10. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell lung cancer Treated with PD-1/pd-l1 Inhibitors: A Single Institutional Cohort Study.
    Yuan Q; Xu C; Wang W; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
    Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
    [No Abstract]    [Full Text] [Related]  

  • 13. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.
    Zhang P; Pei S; Zhou G; Zhang M; Zhang L; Zhang Z
    J Cell Mol Med; 2024 Apr; 28(8):e18284. PubMed ID: 38597415
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and pd-l1: a case report.
    Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
    J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
    Dziadek S; Kraxner A; Cheng WY; Ou Yang TH; Flores M; Theiss N; Tsao TS; Andersson E; Harring SV; Bröske AE; Ceppi M; Teichgräber V; Charo J
    Front Immunol; 2024; 15():1352615. PubMed ID: 38558814
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
    Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
    Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.
    Mei T; Wang T; Zhou Q
    Clin Exp Med; 2024 Mar; 24(1):60. PubMed ID: 38554212
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
    Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Single-cell RNA sequencing integrated with bulk RNA sequencing analysis identifies a tumor immune microenvironment-related lncRNA signature in lung adenocarcinoma.
    Ren Y; Wu R; Li C; Liu L; Li L; Weng S; Xu H; Xing Z; Zhang Y; Wang L; Liu Z; Han X
    BMC Biol; 2024 Mar; 22(1):69. PubMed ID: 38519942
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Inhibition of pd-l1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
    Shi Y; Li W; Jia Q; Wu J; Wu S; Wu S
    Exp Cell Res; 2024 Apr; 437(1):113996. PubMed ID: 38508327
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 46.